A-to-Z study

A-to-Z study

A trial comparing:
(1) Enoxaparin with unfractionated heparin (UFH) therapy in high-risk acute coronary syndrome patients also treated with the GP IIb/IIIa blocker tirofiban/Aggrastat; and
(2) Early vs delayed simvastatin/Zocor therapy.
 
Primary endpoint
Major acute coronary events.
 
Conclusion
Death/MI/refractory ischemia were slightly higher with UFH than with enoxaparin, but not statistically significant.

Logistics
Randomised; 3987 ACS patients: enoxaparin or UFH.